Tech guru, Elon Musk, CEO of X (formerly Twitter), announced that Neuralink, his brain-computer interface company, has achieved a historic milestone by successfully implanting its wireless brain chip in a human for the first time.
Musk shared the news on X, stating that the recipient of the implant is recovering well, with initial results demonstrating promising neuron spike detection.
These spikes, indicative of neuronal activity, are crucial for transmitting information within the brain and to the body.
In a subsequent post on X, Musk unveiled Neuralink’s first product, named Telepathy.
Telepathy aims to revolutionize communication by allowing users to control their devices, including phones and computers, through mere thought. Musk emphasized that initial users will be individuals who have lost limb functionality, envisioning a future where communication transcends physical limitations, citing Stephen Hawking’s struggle with motor neurone disease as inspiration.
The US Food and Drug Administration (FDA) granted Neuralink clearance to conduct its inaugural trial study, dubbed “The PRIME Study,” which focuses on assessing the safety and functionality of the implant in enabling paralyzed individuals to control external devices using their thoughts.
Neuralink’s statement outlined the PRIME Study’s methodology, involving the use of the R1 Robot to precisely implant the N1 Implant’s ultra-fine threads into the brain region controlling movement intention.
The implant, designed to be cosmetically invisible, wirelessly transmits brain signals to an app for decoding, initially aiming to grant users the ability to control computer cursors or keyboards using their thoughts alone.
The PRIME Study, conducted under FDA’s investigational device exemption (IDE), marks a significant stride in Neuralink’s mission to create a universal brain interface, offering hope to those with quadriplegia due to cervical spinal cord injury or ALS.
